Sorafenat 200mg Tablet 30's

About

Sorafenib is an oral multikinase inhibitor that targets several kinases crucial for both tumor cell proliferation and angiogenesis. It exerts its therapeutic effect by inhibiting various intracellular and cell surface kinases, including RAF-1, B-RAF, VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, and FLT-3. This comprehensive inhibition disrupts multiple signaling pathways essential for cancer growth and survival. The dual mechanism of action, targeting both the tumor cells directly and their blood supply, effectively helps to reduce tumor growth and slow the progression of certain cancers. It is particularly indicated for advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and differentiated thyroid carcinoma that has become refractory to radioactive iodine treatment. Its targeted action aims to provide a more specific and effective therapeutic approach compared to traditional, less selective chemotherapy regimens, offering a significant benefit in managing these challenging malignancies.

Uses

• Treatment of advanced renal cell carcinoma.
• Management of unresectable hepatocellular carcinoma.
• Therapy for differentiated thyroid carcinoma refractory to radioactive iodine.
• Used when other treatments have been unsuccessful or are not suitable.

Directions For Use

Take this medication orally, usually twice daily, with or without food. Swallow the tablets whole with water.

Benefits

• Targets multiple pathways involved in cancer growth.
• Effective in slowing disease progression in specific cancers.
• Oral administration offers convenience for patients.
• May improve overall survival in certain advanced cancers.
• Provides a targeted therapy option.
• Approved for use in several difficult-to-treat malignancies.

Side Effects

• Diarrhea
• Hand-foot skin reaction
• Fatigue
• Rash
• Hypertension
• Nausea
• Vomiting
• Anorexia
• Weight loss
• Hair loss
• Bleeding events
• Increased lipase/amylase

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver-related side effects or interact with the medication.
• Pregnancy - Sorafenib is contraindicated in pregnancy due to potential fetal harm. Effective contraception is required during treatment and for a period after.
• Breastfeeding - Breastfeeding is not recommended during Sorafenib treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with pre-existing liver impairment; dose adjustments may be necessary, and liver function should be monitored closely.
• Kidney - Generally, no dose adjustment is needed for mild to moderate renal impairment, but caution is advised in severe cases, and monitoring is recommended.
• Lung - Rare but serious lung toxicities, including interstitial lung disease, have been reported; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.